search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • What's New in Practice Management & Payment

    MIPS Reporting Deadlines Fast Approaching: 10 Things to Do and Know

    CMS MIPS Data Submission Portal Now Available

    2016 Physician Compare Data Now Available

    AMA Releases an Interactive Web-based Tool for MIPS

    CMS Releases 2018 Medicare Physician Fee Schedule Proposed Rule

  • 2018 ID Week logo final
  • News from IDSA and Journals

    4/26/2018

    Bills Recognize Needs for Action, Workforce, to Address Opioid/ID Impacts

    Read More>>

    The Infectious Diseases Society of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society commend House and Senate panels approving legislation this week that demonstrated a commitment to confronting the opioid crisis comprehensively and effectively

  • CDC and FDA Alerts

    4/26/2018 2:46:41 PM

    Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction

    The FDA is warning that the medicine Lamictal (lamotrigine) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system.

    3/6/2018 2:47:49 PM

    Updated Influenza and Hep A Vaccine Resolutions

    In February 2018, ACIP updated influenza vaccine and hepatitis A vaccine resolutions for the Vaccines for Children Program. The changes are:

    2/20/2018 2:47:27 PM

    Multistate Outbreak of Salmonella

    CDC, public health and regulatory officials in several states, and the U.S. Food and Drug Administration (FDA) are investigating a multistate outbreak of Salmonella I 4,[5],12:b:- infections.

    1/19/2018 11:25:10 AM

    Levofloxacin in 5 Percent Dextrose 250mg/50mL by AuroMedics: Recall - Presence of Visible Particulate Matter

    AuroMedics Pharma LLC is voluntarily recalling one lot of Levofloxacin in 5% Dextrose Injection 250mg/50mL in a Single-Use flexible container NDC 55150-243-46, Lot CLF160003, Expiry date May 2018, to the hospital level.

    1/8/2018 4:51:03 PM

    Early Season Influenza A(H3N2) Activity and Treatment of Patients with Influenza Antiviral Medications

    The Centers for Disease Control and Prevention (CDC) is providing: 1) a notice about increased influenza A(H3N2) activity and its clinical implications; 2) a summary of influenza antiviral drug treatment recommendations; 3) an update about approved treatment drugs and supply this season; and 4) background information for patients about influenza treatment.

    12/28/2017 4:54:06 PM

    CDC Investigating Multistate Outbreak of E. coli O157:H7 Infections

    CDC, several states, and the U.S. Food and Drug Administration are investigating a multistate outbreak of Shiga toxin-producing E. coli O157:H7 infections (STEC O157:H7) in 13 states. Seventeen illnesses have been reported from California (3), Connecticut (2), Illinois (1), Indiana (1), Michigan (1), Nebraska (1), New Hampshire (2), New York (1), Ohio (1), Pennsylvania (1), Virginia (1), Vermont (1) and Washington (1).

    12/28/2017 2:09:50 PM

    Seasonal Influenza A(H3N2) Activity and Antiviral Treatment of Patients with Influenza

    The Centers for Disease Control and Prevention (CDC) is providing: 1) a notice about increased influenza A(H3N2) activity and its clinical implications; 2) a summary of influenza antiviral drug treatment recommendations; 3) an update about approved treatment drugs and supply this season; and 4) background information for patients about influenza treatment.

    12/19/2017 2:23:09 PM

    Investigation of Salmonella Infection Linked to Rattlesnake Pills

    The Centers for Disease Control and Prevention and the Kansas Department of Health and Environment have linked one person’s Salmonella Oranienburg infection to taking rattlesnake pills.

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site